medRxiv
Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis
Publication
, Preprint
Zhang, A; Puthumana, J; Downing, N; Shah, N; Krumholz, H; Ross, J
2019
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Citation
APA
Chicago
ICMJE
MLA
NLM
Zhang, A., Puthumana, J., Downing, N., Shah, N., Krumholz, H., & Ross, J. (2019). Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis. medRxiv. https://doi.org/10.1101/19007047
Zhang, Audrey, Jeremy Puthumana, Nicholas Downing, Nilay Shah, Harlan Krumholz, and Joseph Ross. “Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis.” MedRxiv, 2019. https://doi.org/10.1101/19007047.
Zhang A, Puthumana J, Downing N, Shah N, Krumholz H, Ross J. Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis. medRxiv. 2019.
Zhang, Audrey, et al. “Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis.” MedRxiv, 2019. Epmc, doi:10.1101/19007047.
Zhang A, Puthumana J, Downing N, Shah N, Krumholz H, Ross J. Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis. medRxiv. 2019.